{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:32:28Z","timestamp":1781109148977,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,18]]},"DOI":"10.7759\/cureus.19726","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T03:08:31Z","timestamp":1637291311000},"source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy: A Case Series"],"prefix":"10.7759","author":[{"given":"Tuong Vi  C","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili Kanthi","family":"Gudipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanya Shyam","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaramakrishna","family":"Depa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Sajnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller M","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016, 22:886-94. 10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40134-017-0256-2","article-title":"Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy","volume":"5","author":"Widmann G","year":"2016","unstructured":"Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2016, 5:59. 10.1007\/s40134-017-0256-2","journal-title":"Curr Radiol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1574886314666190312115648","article-title":"A \"crazy paving\" pattern on CT scan in a patient treated with pembrolizumab","volume":"14","author":"Marvisi M","year":"2019","unstructured":"Marvisi M, Ramponi S, Balzarini L, Mancini C. A \"crazy paving\" pattern on CT scan in a patient treated with pembrolizumab. Curr Drug Saf. 2019, 14:242-5. 10.2174\/1574886314666190312115648","journal-title":"Curr Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi T","year":"2018","unstructured":"Kobayashi T, Iwama S, Yasuda Y, et al.. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc. 2018, 2:241-51. 10.1210\/js.2017-00432","journal-title":"J Endocr Soc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000455014","article-title":"Adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo R","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, et al.. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017, 45:160-9. 10.1159\/000455014","journal-title":"Am J Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management","volume":"39","author":"Kalisz KR","year":"2019","unstructured":"Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune checkpoint inhibitor therapy-related pneumonitis: patterns and management. Radiographics. 2019, 39:1923-37. 10.1148\/rg.2019190036","journal-title":"Radiographics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816636557","article-title":"Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"10","author":"Abdel-Rahman O","year":"2016","unstructured":"Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016, 10:183-93. 10.1177\/1753465816636557","journal-title":"Ther Adv Respir Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino M","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, et al.. PD-1 inhibitor related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016, 22:6051-60. 10.1158\/1078-0432.CCR-16-1320","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2019.01.001","article-title":"Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation","volume":"26","author":"Ueno R","year":"2019","unstructured":"Ueno R, Nemoto M, Uegami W, Fukuoka J, Misawa M. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation. Respir Med Case Rep. 2019, 26:168-70. 10.1016\/j.rmcr.2019.01.001","journal-title":"Respir Med Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar FB","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, et al.. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016, 90:638-47. 10.1016\/j.kint.2016.04.008","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3928-19","article-title":"Renal effects after pembrolizumab treatment for non-small cell lung carcinoma","volume":"59","author":"Oki R","year":"2020","unstructured":"Oki R, Hirakawa Y, Kimura H, et al.. Renal effects after pembrolizumab treatment for non-small cell lung carcinoma. Intern Med. 2020, 59:977-81. 10.2169\/internalmedicine.3928-19","journal-title":"Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74899-immunotherapy-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:44Z","timestamp":1707507044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74899-immunotherapy-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.19726","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,18]]}}}